About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 

LOGIN
My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Nucleic Acid Therapeutics

formerly Oligonucleotides

Co-Editors-in-Chief: Bruce A. Sullenger, PhD and C.A. Stein, MD, PhD

ISSN: 2159-3337 • Published Bimonthly • Online ISSN: 2159-3345

Current Volume: 24

Latest Impact Factor* is 2.213
Combined to include former title Oligonucleotides

*2012 Journal Citation Reports® published by Thomson Reuters, 2013

Featured Press Releases and Editorial Content

  • Industry Group Releases Safety Testing Recommendations for Oligonucleotide-Based Therapeutics...Read More
  • RNA Aptamers Targeted to Plasminogen Activator Inhibitor Can Block Its Anti-Clot-Busting Activity...Read More
  • Special Issue on Exon Skipping
  • Exon Skipping Prevents Formation of Toxic Protein Fragments in Huntington's Disease...Read More
  • A Natural Sugar Delivers DNA Aptamer Drug Inside Tumor Cells...Read More
  • New Study Shows a Breadth of Antisense Drug Activity Across Many Different Organs...Read More
  • Can Toxicity of a DNA Drug Be Predicted and Minimized?...Read More
  • New Therapeutic Strategy Targets Dengue Virus Using Artificial microRNAs...Read More
  • New Method to Sensitize Human Ovarian Cancer Cells to a Targeted Cytotoxic Drug...Read More
    Nanoparticles Boost Therapeutic Potential of siRNA Drugs...Read More

Overview

Nucleic Acid Therapeutics is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal examines many new approaches for using nucleic acids as therapeutic agents or in modifying nucleic acids for therapeutic purposes including: oligonucleotides, gene modification, aptamers, RNA nanoparticles, and ribozymes.  

Nucleic Acid Therapeutics coverage includes:

  • RNAi: siRNAs, shRNAs, and miRNAs
  • Antisense applications; nucleoside and nucleotide analogs and modifications
  • Peptide nucleic acids
  • DNA-modified gene therapy
  • Nucleic acid-based nanoparticles
  • Ethical, legal, and regulatory issues

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center; C.A. Stein, MD, PhD, Department of Oncology, Albert Einstein-Montefiore Cancer Center, Montefiore Medical Center; and Executive Editor Graham C. Parker, PhD; as well as other leading investigators. View the entire editorial board.  

Audience: Molecular biologists, biochemists, DNA and cell biologists, and biopharmaceutical researchers, among others.  

Nucleic Acid Therapeutics is a rapid-publication Journal, with peer review averaging 25 days from submission to first decision, and online publication of the article within four weeks of acceptance.

Society Affiliation

OTSThe Official Journal of Oligonucleotide Therapeutics Society (OTS).

Indexed/Abstracted in:

MEDLINE; PubMed; PubMed Central; Current Contents®/Life Sciences; Science Citation Index Expanded; Social Sciences Citation Index®; Biotechnology Citation Index®; Biological Abstracts; BIOSIS Previews; Journal Citation Reports/Science Edition; Derwent Drug File; EMBASE/Excerpta Medica; EMBiology; Scopus; ProQuest; SIIC Data Bases
 

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    Human Gene Therapy

    Human Gene Therapy

    The definitive rapid-publication journal covering all aspects of gene therapy through original investigations into the transfer and expression of genes in mammals, with in-depth coverage of DNA, RNA, and cell therapies.

    Genetic Testing and Molecular Biomarkers

    Genetic Testing and Molecular Biomarkers

    Covers all areas of molecular, biochemical, and clinical genetic testing; ethical, legal, social, and economic aspects of genetic testing; issues concerning effective genetic counseling; and molecular biomarkers.

    DNA and Cell Biology

    DNA and Cell Biology

    Combining mechanistic and clinical studies from multiple systems in a single resource, the Journal delivers authoritative, peer-reviewed reporting on the latest research in the field of molecular biology.

    ASSAY and Drug Development Technologies

    ASSAY and Drug Development Technologies

    This authoritative, rapidly peer-reviewed journal features original articles, application-oriented technology reviews, and reports in methodology and technology application.

Browse All Publications »